Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, March 31, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the following changes to its Top Management, effective April 1, 2026.
■ Resignation of Top Management (Effective March 31, 2026)
Adam Pearson, Chief Strategy Officer (CStO)
Adam joined the company in 2004, as Director of Strategic Planning for Yamanouchi Europe, where he primarily supported the integration of Yamanouchi and Fujisawa in Europe to form Astellas. After that, he held key positions related to current VALUE Delivery* activities in various European countries. In 2020, he became Head of Corporate Planning, and then Chief Strategy Officer in 2023, based in Tokyo. He helped shape Corporate Strategic Plan 2021 and the upcoming Corporate Strategic Plan 2026, and led the acquisition and integration of Iveric Bio. We would like to express our sincere appreciation for his inspiring passion and vision, recognizing the lasting legacy he leaves at Astellas.
Following the resignation of Adam Pearson, Peter Sandor, M.D., Head of Corporate Strategy, will assume the duties of CStO on an interim basis, effective April 1, 2026.
*VALUE Delivery: Learn more at https://www.astellas.com/content/dam/astellas-com/global/en/documents/integrated-reports/integrated-report-2025-en.pdf
About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of tellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contacts for inquiries or additional information:
Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201
Follow us
